Zoledronic acid add-on therapy for standard-risk Ewing sarcoma patients in the Ewing 2008R1 trial.
Raphael KochLianne M HavemanRuth Lydia LadensteinBenedicte BrichardHeribert JuergensSona CyprovaHenk van den BergWolf HassenpflugAnna RaciborskaTorben EkDaniel BaumhoerGerlinde EgererLeo KagerMarleen RenardPéter HauserStefan E G BurdachJudith V M G BovéeAngela M HongPeter ReichardtJarmila KruseováArne StreitbürgerThomas KuhneTorsten KesslerMarie BernkopfTrude Butterfaß-BahloulCatharina DhoogeSebastian BauerJános KissMichael PaulussenFiona BonarAndreas RanftBeate TimmermannJelena RasconVolker ViethJukka KanervaAndreas FaldumWolfgang HartmannLars HjorthVivek A BhadriMarkus MetzlerAndré B P van KuilenburgUta DirksenPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
In patients with standard-risk localized EWS, there is no additional benefit from maintenance treatment with ZOL.